Irinotecan (hydrochloride trihydrate)
Irinotecan hydrochloride trihydrate ((+) -Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity[1].
Product Specifications
CAS Number
[136572-09-3]
Product Name Alternative
(+) -Irinotecan (hydrochloride trihydrate) ; CPT-11 (hydrochloride trihydrate)
UNSPSC
12352005
Hazard Statement
H302
Target
Autophagy; Topoisomerase
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/irinotecan-hydrochloride-trihydrate.html
Concentration
10mM
Purity
99.89
Solubility
DMSO : 50 mg/mL (ultrasonic) |Ethanol : 3.33 mg/mL (ultrasonic) |H2O : 1.52 mg/mL (ultrasonic; warming)
Smiles
[H]Cl.O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.O.O.O
Molecular Formula
C33H45ClN4O9
Molecular Weight
677.18
Precautions
H302
References & Citations
[1]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56 (3) :219-26.|[2]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49 (4) :329-35. Epub 2002 Jan 30.|[3]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53 (3) :261-6. Epub 2003 Dec 5.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Topo I
Citation 01
J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Acta Biomater. 2025 Aug 12:S1742-7061 (25) 00602-6.|Apoptosis. 2019 Apr;24 (3-4) :312-325.|BMC Med Genomics. 2025 Oct 30;18 (1) :172.|Cancer Cell. 2025 Jul 14;43 (7) :1296-1312.e7.|Cancers (Basel) . 2023 Sep 6;15 (18) :4442.|Front Immunol. 2018 Jan 5:8:1919.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|NPJ Precis Oncol. 2025 Jul 1;9 (1) :207.|Oncogene. 2025 Jun;44 (22) :1678-1693.|Ruperto Carola University Heidelberg. Natural Sciences and Mathematics. 18 March 2022.|Sci Rep. 2024 Nov 26;14 (1) :29265.|Acta Pharm Sin B. 2024 Apr;14 (4) :1677-1692.|Adv Sci (Weinh) . 2025 Jan 31:e2408845.|Adv Sci (Weinh) . 2025 May 8:e2500271.|Apoptosis. 2016 Feb;21 (2) :130-42. |Biochem Pharmacol. 2023 Oct:216:115752.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 16:167471.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomaterials. 2022 Oct:289:121800.|Biomed Pharmacother. 2020 Aug;128:110262.|Biomed Pharmacother. 2023 Jul:163:114751.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Sep 17.|bioRxiv. 2025 Sep 21.|bioRxiv. 2025 Sep 26:2025.09.24.677357.|bioRxiv. 2019 Dec.|Cancer Cell. 2025 Sep 25:S1535-6108 (25) 00393-9.|Cancer Lett. 2023 Feb 1:554:216028.|Cancer Lett. 2026 Jan 28:638:218156.|Cell Biosci. 2023 Nov 25;13 (1) :215.|Cell Death Dis. 2019 Nov 25;10 (12) :887. |Cell Death Dis. 2024 Jun 15;15 (6) :417.|Cell Death Dis. 2025 Apr 5;16 (1) :253.|Cell Death Dis. 2025 Jan 18;16 (1) :28.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Discov. 2022 Sep 14;8 (1) :92.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2024 Mar 19;5 (3) :101468.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell. 2022 Sep 1;185 (18) :3356-3374.e22.|Clin Cancer Res. 2023 Nov 14;29 (22) :4644-4659.|EBioMedicine. 2023 Jun:92:104594.|Eur J Pharm Biopharm. 2022 Feb:171:39-49.|Eur J Pharmacol. 2023 Jun 15:949:175718.|Food Hydrocoll Health. 2025 Jun.|Gastroenterology. 2021 Nov;161 (5) :1601-1614.e23.|Gene. 2019 Mar 10:688:1-6.|Genome Med. 2016 Oct 31;8 (1) :116.|Heliyon. 2023 Apr 27;9 (5) :e15805.|Int J Pharm. 2020 Jun 30:584:119337.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Pharm Pharmacol. 2023 Apr 7;75 (4) :523-532.|Life Sci. 2019 Aug 15:231:116529.|Lung Cancer. 2023 Apr:178:237-246.|Mol Biol Cell. 2023 May 1;34 (5) :ar47.|Mol Cancer Ther. 2021 Dec;20 (12) :2483-2494.|Mol Cancer. 2024 Apr 4;23 (1) :70.|Mol Ther Oncol. 2025 Nov 22.|Mol Cancer Res. 2020 Mar;18 (3) :414-423.|Patent. US20210009719A1.|Pharmacol Res. 2021 Jan;163:105232.|PLoS Biol. 2022 Feb 24;20 (2) :e3001517.|PLoS Pathog. 2020 Mar 24;16 (3) :e1008429.|Redox Biol. 2024 May 23:73:103207.|Res Sq. 2025 Nov 19:rs.3.rs-7682325.|Signal Transduct Target Ther. 2021 May 28;6 (1) :188.|Theranostics. 2019 May 31;9 (13) :3732-3753.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
043439-Biotin 200 µL
TTLL13, ID (TTLL13, Tubulin polyglutamylase TTLL13, Tubulin-tyrosine ligase-like protein 13) (Biotin) discontinued
Ask
View Details 339847-01 50 µg
XRCC3 (DNA Repair Protein XRCC3, X-ray Repair Cross-complementing Protein 3)
Ask
View Details